warnings
WARNINGS: For external use only. Not for ophthalmic use.
Bruselix Gel
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Bruselix Gel
- Generic name
- LIDOCAINE HCI 3.88%
- Manufacturer
- PureTek Corporation
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 1420ec27-64f3-9117-e063-6294a90a8ece
- SPL ID
- 155d0c2a-6027-c589-e063-6394a90a07dd
- Version
- 4
- Effective date
- 2024-04-05
- Source export date
- 2026-10-12
- Source partition
- 5
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0005-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-10-12/13cbfcd236c665f0ee69e2d9141331148dcdff45d1679c92f029cfba27dd74a2/drug-label-0005-of-0014.json.zip
- Source manifest SHA-256
- 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
- Import run
- 20261013T011858Z
- Imported at
- 2026-10-13 01:43:51
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | Bruselix Gel | openfda.brand_name | |
| generic name | LIDOCAINE HCI 3.88% | openfda.generic_name | |
| manufacturer name | PureTek Corporation | openfda.manufacturer_name | |
| ndc | package | 59088-233-05 | openfda.package_ndc |
| ndc | product | 59088-233 | openfda.product_ndc |
| ndc11 | package | 59088023305 | derived:openfda.package_ndc |
| rxcui | 2678305 | openfda.rxcui | |
| rxcui | 2675768 | openfda.rxcui | |
| spl id | 155d0c2a-6027-c589-e063-6394a90a07dd | id | |
| spl set id | 1420ec27-64f3-9117-e063-6294a90a8ece | set_id | |
| unii | V13007Z41A | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS: During or immediately after treatment, the skin at the site of treatment may develop erythema or edema or may be the locus of abnormal sensation.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.